Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarah Karlin-Smith

Set Alert for Articles By Sarah Karlin-Smith

Latest From Sarah Karlin-Smith

Pink Sheet Podcast: Another Coronavirus Stimulus Bill, Remdesivir’s Brief Orphan Status, Teva Sues Over Copaxone Regulation

Pink Sheet editor and reporters discuss the effects of the latest coronavirus stimulus package on pharma, Gilead’s request for rescission of an orphan designation, and Teva’s suit over Copaxone regulation. 

Coronavirus COVID-19 Legislation

Inside The COVID-19 Bill: Breaking Down The Pharma Policy Provisions

What's in – and what fell out of – the massive US stimulus package.

Coronavirus COVID-19 Legislation

Drug Industry Perks Mostly Dropped From COVID-19 Bill, But A Big One Remains

Early versions of US Congress's coronavirus relief bill contained a number of policies that would have benefited drug firms, but they didn't make it into the final bill. However, the $2 trillion package does provide pharmaceutical companies with relief from the threat of drug pricing reform until after the 2020 elections.

Coronavirus COVID-19 Pricing Debate

Drug Pricing Reform In 2020 Gets Harder Due To Third Coronavirus Bill

Senate and House versions of a pending coronavirus stimulus package take off the table a key legislative vehicle lawmakers planned to use to push for bipartisan drug pricing reform until at least after the 2020 elections, signaling a potential reprieve for the pharmaceutical industry. 

Coronavirus COVID-19 Legislation

Gilead's Expanded Access Shift Offers New Data Collection Opportunities For Remdesivir

Pivot from individual- to multi-patient protocols for expanded access may help generate data to inform regulatory filings and even payer determinations for Gilead’s potential COVID-19 treatment.

Coronavirus COVID-19 Drug Approval Standards

US FDA Eases Up On Adverse Event Reporting During COVID-19

Issued as part of the new approach to releasing guidances during the pandemic, FDA said flexibility was needed for two reasons: anticipated higher levels of absenteeism among staff for both sponsors and the agency, and the necessity of prioritizing a focus on adverse events for products used to treat coronavirus.

Safety Coronavirus COVID-19
See All
UsernamePublicRestriction

Register